Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.35 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | TEAD3 | Q99594 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | UGCG | Q16739 | 1/20 | 0.33 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22110281 | 0.80 | SLC18A2 (0.43) | CHRNB2CHRNA7CHRNA4CHRNA5POLB | |
| SCHEMBL22110352 | 0.70 | KDM4E (0.48) | SLC18A2LTA4H | |
| SCHEMBL22110450 | 0.69 | CHRM3 (0.49) | CHRNB2CHRNA7CHRNA4CHRNA5POLB | |
| SCHEMBL8806151 | 0.69 | ADRA2A (0.52) | CHRNB2CHRNA7CHRNA4CHRNA5LTA4H | |
| SCHEMBL22110286 | 0.69 | CHRM3 (0.49) | CHRNB2CHRNA7CHRNA4CHRNA5POLB | |
| SCHEMBL23073695 | 0.65 | TSHR (0.47) | — | |
| SCHEMBL14509642 | 0.65 | LTA4H (0.45) | LTA4HTEAD3GBA1UGCGGBA2 | |
| SCHEMBL6166949 | 0.63 | TRPV6 (0.51) | SLC18A2 | |
| SCHEMBL4197627 | 0.63 | SLC6A2 (0.40) | AGTR2POLBLTA4HTEAD3 | |
| SCHEMBL15341688 | 0.63 | TSHR (0.44) | AGTR2LTA4HGBA1UGCGGBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200190099-A1 | NOVEL PYRIMIDINE DERIVATIVE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION PROCESS THEREOF, AND PHARMACEUTICAL COMPOSITION USING THE SAME | SPARK BIOPHARM, INC. (KR) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190099-A1 | NOVEL PYRIMIDINE DERIVATIVE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION PROCESS THEREOF, AND PHARMACEUTICAL COMPOSITION USING THE SAME | DPYD, NUDT1, NUDT5 | ACE2 430/4885CHRNB2 4778/4885CHRNA7 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.